Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 7/20 | 0.54 |
| ▸ | MDM4 | O15151 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | CASP3 | P42574 | 2/20 | 0.51 |
| ▸ | TLR2 | O60603 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20529763 | 1.00 | MDM2 (0.54) | MDM2MDM4TP53CASP3TLR2 | |
| SCHEMBL20876883 | 1.00 | MDM2 (0.54) | MDM2MDM4TP53CASP3TLR2 | |
| SCHEMBL1272388 | 1.00 | MDM2 (0.54) | MDM2MDM4TP53CASP3TLR2 | |
| SCHEMBL30851391 | 1.00 | MDM2 (0.54) | MDM2MDM4TP53CASP3TLR2 | |
| SCHEMBL15942924 | 0.97 | MDM2 (0.54) | MDM2MDM4TP53CASP3TLR2 | |
| SCHEMBL20876881 | 0.97 | MDM2 (0.54) | MDM2MDM4TP53CASP3TLR2 | |
| SCHEMBL34461960 | 0.97 | MDM2 (0.54) | MDM2MDM4TP53CASP3TLR2 | |
| SCHEMBL34461958 | 0.97 | MDM2 (0.54) | MDM2MDM4TP53CASP3TLR2 | |
| SCHEMBL31013089 | 0.97 | MDM2 (0.54) | MDM2MDM4TP53CASP3TLR2 | |
| SCHEMBL20876827 | 0.96 | MDM2 (0.53) | MDM2MDM4TP53CASP3TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600757-B2 | Peptides inhibiting gamma-c-cytokine activity and methods of use | Bioniz Therapeutics, Inc. (US) | 2026-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600757-B2 | Peptides inhibiting gamma-c-cytokine activity and methods of use | IL15, IL2, IL15RA | MDM2 2855/4885MDM4 4824/4885TP53 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.